Board Of Directors

Committees:

• Value Creation

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Global Business
• Investment Management
• Growth Strategies and Market Expansion
• Operations Experience

Expertise Provided to the Board:

John Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He has two decades of experience leading global companies in life sciences, medical devices, and diagnostics.

Prior to joining the company, Mr. Marotta served as Executive in Residence of Patient Square Capital, a leading healthcare investment firm. Previously, he served as CEO and President of PHC Holdings Corp. (TSE: 6523) (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues, and leading its IPO from owners KKR Capital. He also held a variety of senior executive roles in leading life sciences companies, including Danaher (NYSE: DHR), Envista Holdings (NYSE: NVST), and Cardinal Health (NYSE: CAH), where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions.

Committees:

• Audit (Chair)
• Nominating and Governance

Attributes and Skills Provided to the Board:

• Global Business
• Financial Management, Accounting and Audit
• Risk and Investment Management
• Financing transactions
• M&A Integration Experience
• Experience in highly regulated industries
• Talent and Leadership Development

Expertise Provided to the Board:

Frank E. Casal is the Chair of the Azenta Board. He formerly served as Vice Chair of Audit of KPMG, where he spent over forty years of his career. Mr. Casal brings best-in-class knowledge of financial reporting, accounting and audit to the Azenta Board, drawing on his experience providing supervisory responsibilities to large, global Fortune 500 companies. Mr. Casal has significant expertise in transforming businesses through mergers and acquisitions, financing transactions and other strategic priorities. Having led the Audit function of approximately 9,000 professionals at KPMG, he has proven leadership and management experience, offering unique perspective to the Azenta Board’s ongoing efforts to manage talent and human capital.

Committees:

• Human Resources and Compensation
• Value Creation

Attributes and Skills Provided to the Board:

• Risk and Investment Management
• Strategy, Financial Management and Governance
• Public Company Director and Board Committee Leadership Experience
• Capital Allocation
• Fundamental Valuation and Corporate Management Analysis

Expertise Provided to the Board:

Quentin G. Koffey brings his expertise as a professional investor as Founder, Managing Partner and Chief Investment Officer of Politan Capital Management. Prior to founding Politan in 2021, Mr. Koffey was a partner at Senator Investment Group LP from 2019 to 2021, a Portfolio Manager for Strategic Investments at The D.E. Shaw Group from 2017 to 2019 and a Portfolio Manager at Elliott Management Corporation from 2010 to 2017. Mr. Koffey brings his expertise as a professional investor, as well as his experience enhancing strategy, financial management, and governance in the healthcare sector.

Committees:

• Value Creation

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Global Business
• Experience in Highly Regulated Industries
• Growth Strategies and Market Expansion
• Operations Experience

Expertise Provided to the Board:

Alan J. Malus brings experience from his service as the former Corporate Executive Vice President of Thermo Fisher (NYSE: TMO), where he also formerly served as former President, Laboratory Products and Services. He also held various leadership positions and senior executive positions in finance, marketing, commercial development and operations since joining Thermo Fisher in 1998. Previously, he served as an independent director at PHC Holdings Corp. (TSE: 6523), a global healthcare company headquartered in Japan. Mr. Malus brings over 18 years of broad reaching executive and operating experience in the life sciences, global healthcare, and diagnostics industry, with experience in enhancing growth strategies and market expansion.

Committees:

• Value Creation (Chair)

Attributes and Skills Provided to the Board:

• Investment Management
• Growth Strategies and Market Expansion
• Public Company Director Experience
• M&A and Integration Experience
• Fundamental Valuation and Corporate Management Analysis
• Information Security Experience

Expertise Provided to the Board:

William L. Cornog brings his expertise as the former head of KKR Capstone, the portfolio operations team of KKR & Co. In addition to leading Capstone, Mr. Cornog chaired KKR’s portfolio management committees for the Americas, Europe, Asia, Infrastructure, Impact & Technology Growth and was a member of the Investment & Distribution and Valuation Committees. Mr. Cornog brings extensive experience in financial investment, advisory and monitoring, as well as global portfolio experience.

Committees:

• Environmental, Social and Governance
• Human Resources and Compensation

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Public Company Executive Experience
• Global Business Experience
• Operational Experience
• Growth Strategy and Market Expansion
• M&A and Integration Experience

Expertise Provided to the Board:

Tina S. Nova is an industry veteran in life sciences, with deep experience in building and leading successful life science businesses from conception through IPO, including public-company CEO experience. She has deep insights into commercial operations, sales and marketing efforts, as well as extensive experience in the creation of start-up companies and the commercialization of products with a focus on molecular diagnostics. Ms. Nova brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director that created value for shareholders. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, until its $600 million sale to Veracyte (NASDAQ: VCYT) in 2021, Molecular Stethoscope and Genoptix, which she spent 15 years as the co-founder and oversaw its $470 million sale to Novartis AG (NYSE: NVS) in 2011.

Committees:

• Environmental, Social and Governance (Chair)
• Audit

Attributes and Skills Provided to the Board:

• Global Business Experience
• Public Company Executive Experience
• Financial Management, Accounting and Audit
• Growth Strategy and Market Expansion
• ESG/Sustainability
• M&A and Integration Experience
• Leadership and Talent Development

Expertise Provided to the Board:

Erica J. McLaughlin currently serves as Executive Vice President, CFO and Head of Corporate Strategy at Cabot Corporation (NYSE: CBT), a publicly traded manufacturer of specialty chemicals and performance materials. Ms. McLaughlin brings extensive international business experience and expertise in financial areas and strategy, with a strong background in accounting and audit. She also has significant experience in mergers, acquisitions and integrations, as well as industrial knowledge of life sciences, having served on Azenta’s Board during its transition from Brooks Automation. Further, her experience both as the Inaugural Chairperson of Cabot’s Diversity and Inclusion Steering Committee and as Co-Chair of the Governance pillar at Cabot’s ESG executive management structure, gives her a valuable perspective on ESG, DEI, and other matters top-of-mind for Azenta’s leadership.

Committees:

• Nominating and Governance (Chair)
• Value Creation

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Growth Strategies and Market Expansion
• Investment Management
• Global Business
• Public Company Director Experience
• M&A and Integration Experience

Expertise Provided to the Board:

Dr. Martin Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. An experienced public-company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member, he brings valuable operational insight and industry expertise to the Azenta Board. Dr. Madaus has a proven track record of creating shareholder value in both public and private life science companies. He has notable experience in strategy, mergers and acquisitions and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG).

Committees:

• Human Resources and Compensation (Chair)
• Nominating and Governance

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Risk and Investment Management
• Operations Experience
• Growth Strategy and Market Expansion
• M&A and Integration Experience
• Talent and Leadership Development
• Public Company Director Experience

Expertise Provided to the Board:

Since 2000, Robyn C. Davis has served as Managing Director at AngelHealthcare Investors, a group comprised of Boston-based health and investment leaders. Ms. Davis manages the investment process and the portfolio of early-stage investments including medical devices, life sciences, information technology, and professional services. She served on the boards of several portfolio companies and actively contributed to their fundraising, business model, and successful exit. Ms. Davis brings valuable investor-focused perspective to the Azenta Board and its ongoing efforts to maximize shareholder value. She also has strong financial acumen, particularly as it relates to operational matters, and extensive experience supporting life sciences companies as they scale and grow, both organically and through mergers and acquisitions, having successfully exited certain portfolio companies and having sat on the Board of CRA Health when it was acquired by Volpara.

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Public Company Executive Experience
• Growth Strategies and Market Expansion
• Operations Experience

Expertise Provided to the Board:

Dipal Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors, where he previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning, and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. Earlier in his career, he has held senior-level positions at a healthcare private equity fund and Catalent, Merrill Lynch’s Investment Banking Group, as well as several roles at Eli Lilly and Company. Mr. Doshi brings significant experience in the biotechnology and pharmaceutical industries. His experience in strategy, operational and commercial growth, and perspective as a current public company CEO will be additive to the Board.

Committees:

• Value Creation

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Global Business
• Investment Management
• Growth Strategies and Market Expansion
• Operations Experience

Expertise Provided to the Board:

John Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He has two decades of experience leading global companies in life sciences, medical devices, and diagnostics.

Prior to joining the company, Mr. Marotta served as Executive in Residence of Patient Square Capital, a leading healthcare investment firm. Previously, he served as CEO and President of PHC Holdings Corp. (TSE: 6523) (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company focused on precision healthcare, growing global revenues, and leading its IPO from owners KKR Capital. He also held a variety of senior executive roles in leading life sciences companies, including Danaher (NYSE: DHR), Envista Holdings (NYSE: NVST), and Cardinal Health (NYSE: CAH), where he demonstrated consistent achievement in organic revenue growth, operational efficiencies, and significant value-creating transactions.

Committees:

• Audit (Chair)
• Nominating and Governance

Attributes and Skills Provided to the Board:

• Global Business
• Financial Management, Accounting and Audit
• Risk and Investment Management
• Financing transactions
• M&A Integration Experience
• Experience in highly regulated industries
• Talent and Leadership Development

Expertise Provided to the Board:

Frank E. Casal is the Chair of the Azenta Board. He formerly served as Vice Chair of Audit of KPMG, where he spent over forty years of his career. Mr. Casal brings best-in-class knowledge of financial reporting, accounting and audit to the Azenta Board, drawing on his experience providing supervisory responsibilities to large, global Fortune 500 companies. Mr. Casal has significant expertise in transforming businesses through mergers and acquisitions, financing transactions and other strategic priorities. Having led the Audit function of approximately 9,000 professionals at KPMG, he has proven leadership and management experience, offering unique perspective to the Azenta Board’s ongoing efforts to manage talent and human capital.

Committees:

• Human Resources and Compensation
• Value Creation

Attributes and Skills Provided to the Board:

• Risk and Investment Management
• Strategy, Financial Management and Governance
• Public Company Director and Board Committee Leadership Experience
• Capital Allocation
• Fundamental Valuation and Corporate Management Analysis

Expertise Provided to the Board:

Quentin G. Koffey brings his expertise as a professional investor as Founder, Managing Partner and Chief Investment Officer of Politan Capital Management. Prior to founding Politan in 2021, Mr. Koffey was a partner at Senator Investment Group LP from 2019 to 2021, a Portfolio Manager for Strategic Investments at The D.E. Shaw Group from 2017 to 2019 and a Portfolio Manager at Elliott Management Corporation from 2010 to 2017. Mr. Koffey brings his expertise as a professional investor, as well as his experience enhancing strategy, financial management, and governance in the healthcare sector.

Committees:

• Value Creation

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Global Business
• Experience in Highly Regulated Industries
• Growth Strategies and Market Expansion
• Operations Experience

Expertise Provided to the Board:

Alan J. Malus brings experience from his service as the former Corporate Executive Vice President of Thermo Fisher (NYSE: TMO), where he also formerly served as former President, Laboratory Products and Services. He also held various leadership positions and senior executive positions in finance, marketing, commercial development and operations since joining Thermo Fisher in 1998. Previously, he served as an independent director at PHC Holdings Corp. (TSE: 6523), a global healthcare company headquartered in Japan. Mr. Malus brings over 18 years of broad reaching executive and operating experience in the life sciences, global healthcare, and diagnostics industry, with experience in enhancing growth strategies and market expansion.

Committees:

• Value Creation (Chair)

Attributes and Skills Provided to the Board:

• Investment Management
• Growth Strategies and Market Expansion
• Public Company Director Experience
• M&A and Integration Experience
• Fundamental Valuation and Corporate Management Analysis
• Information Security Experience

Expertise Provided to the Board:

William L. Cornog brings his expertise as the former head of KKR Capstone, the portfolio operations team of KKR & Co. In addition to leading Capstone, Mr. Cornog chaired KKR’s portfolio management committees for the Americas, Europe, Asia, Infrastructure, Impact & Technology Growth and was a member of the Investment & Distribution and Valuation Committees. Mr. Cornog brings extensive experience in financial investment, advisory and monitoring, as well as global portfolio experience.

Committees:

• Environmental, Social and Governance
• Human Resources and Compensation

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Public Company Executive Experience
• Global Business Experience
• Operational Experience
• Growth Strategy and Market Expansion
• M&A and Integration Experience

Expertise Provided to the Board:

Tina S. Nova is an industry veteran in life sciences, with deep experience in building and leading successful life science businesses from conception through IPO, including public-company CEO experience. She has deep insights into commercial operations, sales and marketing efforts, as well as extensive experience in the creation of start-up companies and the commercialization of products with a focus on molecular diagnostics. Ms. Nova brings significant experience in mergers, acquisitions and integration, having overseen the sale of several companies as both an executive and director that created value for shareholders. She also provides relevant life sciences executive leadership experience, having held Chief Executive roles at Decipher Biosciences, until its $600 million sale to Veracyte (NASDAQ: VCYT) in 2021, Molecular Stethoscope and Genoptix, which she spent 15 years as the co-founder and oversaw its $470 million sale to Novartis AG (NYSE: NVS) in 2011.

Committees:

• Environmental, Social and Governance (Chair)
• Audit

Attributes and Skills Provided to the Board:

• Global Business Experience
• Public Company Executive Experience
• Financial Management, Accounting and Audit
• Growth Strategy and Market Expansion
• ESG/Sustainability
• M&A and Integration Experience
• Leadership and Talent Development

Expertise Provided to the Board:

Erica J. McLaughlin currently serves as Executive Vice President, CFO and Head of Corporate Strategy at Cabot Corporation (NYSE: CBT), a publicly traded manufacturer of specialty chemicals and performance materials. Ms. McLaughlin brings extensive international business experience and expertise in financial areas and strategy, with a strong background in accounting and audit. She also has significant experience in mergers, acquisitions and integrations, as well as industrial knowledge of life sciences, having served on Azenta’s Board during its transition from Brooks Automation. Further, her experience both as the Inaugural Chairperson of Cabot’s Diversity and Inclusion Steering Committee and as Co-Chair of the Governance pillar at Cabot’s ESG executive management structure, gives her a valuable perspective on ESG, DEI, and other matters top-of-mind for Azenta’s leadership.

Committees:

• Nominating and Governance (Chair)
• Value Creation

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Growth Strategies and Market Expansion
• Investment Management
• Global Business
• Public Company Director Experience
• M&A and Integration Experience

Expertise Provided to the Board:

Dr. Martin Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. An experienced public-company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member, he brings valuable operational insight and industry expertise to the Azenta Board. Dr. Madaus has a proven track record of creating shareholder value in both public and private life science companies. He has notable experience in strategy, mergers and acquisitions and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG).

Committees:

• Human Resources and Compensation (Chair)
• Nominating and Governance

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Risk and Investment Management
• Operations Experience
• Growth Strategy and Market Expansion
• M&A and Integration Experience
• Talent and Leadership Development
• Public Company Director Experience

Expertise Provided to the Board:

Since 2000, Robyn C. Davis has served as Managing Director at AngelHealthcare Investors, a group comprised of Boston-based health and investment leaders. Ms. Davis manages the investment process and the portfolio of early-stage investments including medical devices, life sciences, information technology, and professional services. She served on the boards of several portfolio companies and actively contributed to their fundraising, business model, and successful exit. Ms. Davis brings valuable investor-focused perspective to the Azenta Board and its ongoing efforts to maximize shareholder value. She also has strong financial acumen, particularly as it relates to operational matters, and extensive experience supporting life sciences companies as they scale and grow, both organically and through mergers and acquisitions, having successfully exited certain portfolio companies and having sat on the Board of CRA Health when it was acquired by Volpara.

Attributes and Skills Provided to the Board:

• Executive Leadership in Life Sciences/Healthcare
• Public Company Executive Experience
• Growth Strategies and Market Expansion
• Operations Experience

Expertise Provided to the Board:

Dipal Doshi is the CEO of Entrada Therapeutics and a Member of its Board of Directors, where he previously served as President and CEO from 2017 to 2023. Mr. Doshi has led critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning, and finance. Prior to joining Entrada, Mr. Doshi was the Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. Earlier in his career, he has held senior-level positions at a healthcare private equity fund and Catalent, Merrill Lynch’s Investment Banking Group, as well as several roles at Eli Lilly and Company. Mr. Doshi brings significant experience in the biotechnology and pharmaceutical industries. His experience in strategy, operational and commercial growth, and perspective as a current public company CEO will be additive to the Board.